List of Excipients in Branded Drug BETAMETHASONE VALERATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
E Fougera & Co a division of Fougera Pharmaceuticals LLC	BETAMETHASONE VALERATE	betamethasone valerate	0168-0040	CETOSTEARYL ALCOHOL
E Fougera & Co a division of Fougera Pharmaceuticals LLC	BETAMETHASONE VALERATE	betamethasone valerate	0168-0040	CHLOROCRESOL
E Fougera & Co a division of Fougera Pharmaceuticals LLC	BETAMETHASONE VALERATE	betamethasone valerate	0168-0040	MINERAL OIL

Generic Drugs Containing BETAMETHASONE VALERATE

Company	Ingredient	NDC	Excipient
Actavis Pharma Inc	betamethasone valerate	0472-0370	CETETH-20
Actavis Pharma Inc	betamethasone valerate	0472-0370	CETOSTEARYL ALCOHOL
Actavis Pharma Inc	betamethasone valerate	0472-0370	CHLOROCRESOL

What are the Most Frequently-Used Excipients in BETAMETHASONE VALERATE?

# Of NDCs	Excipient
6	ALCOHOL
5	ANHYDROUS CITRIC ACID
2	AQUA

Betamethasone Valerate Excipient Strategy and Commercial Opportunities

Last updated: August 8, 2026

Betamethasone valerate is an established topical corticosteroid with limited active-ingredient exclusivity and a predominantly generic market. Commercial value now depends on formulation performance, delivery format, tolerability, manufacturing efficiency, and channel-specific differentiation. The strongest opportunities are low-residue scalp and body products, foam and spray delivery, preservative-conscious formulations, pediatric-use positioning, and combinations with differentiated moisturization or barrier-support systems.

What is the commercial status of betamethasone valerate?

Betamethasone valerate is a synthetic glucocorticoid used topically for corticosteroid-responsive dermatoses, including eczema, dermatitis, and psoriasis. It is generally classified as a medium- to high-potency topical corticosteroid depending on formulation and jurisdiction.

In the United States, betamethasone valerate is marketed in products such as creams, ointments, lotions, and foam. The active ingredient is distinct from betamethasone dipropionate, which is used in products such as augmented betamethasone dipropionate ointment and gel.

Attribute	Betamethasone valerate
Therapeutic class	Topical corticosteroid
Main route	Dermal
Common strength	0.1%
Foam strength	Approximately 0.12% in the U.S. reference product
Typical indications	Atopic dermatitis, eczema, contact dermatitis, psoriasis
Regulatory pathway	Generic ANDA products and branded NDA products
Biosimilar relevance	None
Primary commercial competition	Other topical corticosteroids, generic betamethasone products, branded vehicles
Core differentiation lever	Vehicle and delivery system

Betamethasone valerate has been commercially available for decades. The molecule itself does not provide a durable exclusivity platform. The commercial asset is the finished dosage form.

What excipients are used in betamethasone valerate formulations?

Excipients vary by dosage form. The formulation objective is to dissolve or disperse the corticosteroid, control release into the stratum corneum, maintain physical stability, support skin tolerability, and provide acceptable sensory properties.

Cream excipients

Common cream systems may include:

• Water
• Mineral oil
• Petrolatum
• Propylene glycol
• Cetostearyl alcohol
• Stearyl alcohol
• Glyceryl stearate
• Polysorbates
• Carbomer or other rheology modifiers
• Preservatives such as parabens or phenoxyethanol
• pH adjusters and buffers

A cream is usually the most commercially accessible format because it supports broad body-site use and familiar prescribing behavior. Its main disadvantages are preservative exposure, potential stinging from glycols, and lower patient preference compared with lighter or faster-drying vehicles.

Ointment excipients

Ointments generally rely on hydrophobic bases such as:

• White petrolatum
• Mineral oil
• Paraffin
• Microcrystalline wax
• Polyethylene or other structured hydrocarbons

Ointments improve occlusion and can increase hydration of the stratum corneum. They are suitable for dry, thickened, or lichenified lesions. The commercial limitation is cosmetic acceptability. Greasiness can reduce adherence, particularly for scalp, facial, intertriginous, and daytime use.

Lotion excipients

Lotions commonly contain:

• Purified water
• Alcohols
• Glycols
• Emulsifiers
• Hydrocarbon oils
• Carbomers
• Preservatives
• Fragrance-free sensory modifiers

Lotion is useful for large body surfaces and hairy areas. Low-viscosity systems can improve spreadability but may create runoff, dripping, or dose variability. A controlled-viscosity lotion may offer a better balance between scalp application and body coverage.

Foam excipients

Topical foam products generally use a volatile propellant system and a hydroalcoholic or emulsion-based vehicle. Potential excipient classes include:

• Ethanol
• Water
• Glycols
• Emulsifiers
• Fatty alcohols
• Hydrocarbon propellants
• Corrosion-control components
• Stabilizers

Foam is commercially attractive because it spreads quickly, has lower perceived greasiness, and can be applied to hair-bearing areas. The manufacturing and regulatory burden is higher than for a conventional cream. Packaging, valve performance, fill weight, flammability controls, propellant compatibility, and microbial control all affect product quality.

How should an excipient strategy be designed for betamethasone valerate?

The preferred strategy is to select the vehicle around the treatment site and patient behavior rather than simply reproduce a conventional generic cream.

Optimize drug solubilization

Betamethasone valerate has limited water solubility. A formulation may use a cosolvent system, an emulsion, a suspension, or a combination of dissolved and dispersed drug. Propylene glycol and ethanol can improve solubilization but may increase irritation or stinging, particularly on fissured or inflamed skin.

The target should be a stable, uniform drug distribution through the labeled shelf life. Developers should assess:

• Assay and content uniformity
• Particle size if the drug is suspended
• Polymorphic or crystalline changes
• In vitro release
• Skin permeation
• Viscosity and rheology
• Phase separation
• Preservative effectiveness
• Container compatibility

Control corticosteroid delivery

The vehicle affects the amount of corticosteroid available at the skin surface and the rate of penetration. Occlusive ointments can enhance hydration and drug penetration. Alcohol-containing systems can dry rapidly but may sting. Foam may deliver a less greasy layer with rapid spreading across hair-bearing skin.

The objective is not maximum penetration. Excessive delivery can increase the risk of local adverse effects such as skin atrophy, striae, telangiectasia, and hypothalamic-pituitary-adrenal axis suppression with extensive or prolonged use. Product design must remain consistent with the potency and labeling of the reference product. FDA labeling for topical corticosteroids emphasizes use of the lowest effective potency and duration appropriate for the condition (U.S. Food and Drug Administration [FDA], 2023a).

Minimize irritation

Potential irritation drivers include:

• Ethanol and isopropanol
• Propylene glycol
• High surfactant concentrations
• Acidic or alkaline pH
• Preservatives
• Fragrance
• Essential oils
• High volatile-solvent content

A preservative-free or low-preservative system may have value for sensitive-skin populations, but it requires validated microbial control through packaging, water activity, manufacturing controls, and container-closure testing.

Improve sensory performance

Patient adherence is strongly affected by greasiness, residue, odor, drying time, and ease of application. Commercially relevant targets include:

• Rapid rub-in
• Low tack
• Minimal white residue
• Non-greasy after-feel
• No fragrance
• Low transfer to clothing
• Easy dosing on the scalp
• Stable viscosity across temperature ranges

These attributes can support a branded or authorized-generic strategy even when the active ingredient is interchangeable.

What formulations are protected by betamethasone valerate patents?

The active ingredient is an old corticosteroid, so composition-of-matter exclusivity is not a current commercial barrier. Protection is more likely to arise from:

• Specific vehicle compositions
• Foam or aerosol systems
• Container-closure systems
• Manufacturing processes
• Stabilization systems
• Combination products
• Narrow method-of-use claims
• Device-assisted delivery

Any patent strategy must be evaluated against the current U.S. Patent and Trademark Office database, FDA Orange Book listings, and relevant national registers. Patentability is more credible where the formulation produces a measurable technical result, such as improved stability, reduced irritation, enhanced scalp deposition, or a defined in vitro release profile.

A conventional cream containing betamethasone valerate, petrolatum, water, and standard emulsifiers is unlikely to provide a strong new-patent position unless the formulation has an unexpected performance advantage supported by comparative data.

What is the Orange Book status of betamethasone valerate?

Betamethasone valerate products can enter through the abbreviated new drug application pathway when a proposed product demonstrates pharmaceutical equivalence and bioequivalence or meets the applicable topical product requirements. FDA’s Orange Book identifies reference listed drugs, approved products, therapeutic equivalence codes, and patent or exclusivity information where applicable (FDA, 2023b).

The principal regulatory considerations are:

Issue	Commercial implication
Reference listed drug selection	Determines the comparator for an ANDA
Dosage form	Cream, ointment, lotion, and foam may require separate development programs
Strength	A formulation cannot assume automatic substitutability across strengths
Vehicle composition	May affect pharmaceutical equivalence and performance testing
Patent listing	Determines whether a Paragraph IV certification is needed
Exclusivity	May delay approval or commercial launch despite patent expiry
Therapeutic equivalence	Determines substitution potential at the pharmacy level

For topical semisolid products, FDA may require comparative characterization, in vitro release testing, and, depending on the product and regulatory framework, additional clinical or dermatopharmacokinetic evidence. The regulatory path is product-specific.

When does betamethasone valerate lose exclusivity?

Betamethasone valerate has already lost active-ingredient exclusivity in the United States and major international markets. The relevant commercial barriers are product-specific patents, regulatory exclusivity, and market access.

Exclusivity category	Current strategic relevance
Composition-of-matter patent	Generally expired or commercially irrelevant
New chemical entity exclusivity	Not applicable to a mature active ingredient
Pediatric exclusivity	Not a central barrier for established products
Formulation patent	Relevant only for specific protected vehicles
Method-of-use patent	Potentially relevant for narrow indications
Orphan exclusivity	Generally not applicable
Biosimilar exclusivity	Not applicable
ANDA first-filer exclusivity	Possible only if a qualifying Paragraph IV opportunity exists

Generic entry can occur without a new patent challenge where the proposed product references an unprotected listed product or where applicable patents have expired. A Paragraph IV challenge remains relevant only if a listed patent creates a meaningful approval barrier.

Which companies are challenging betamethasone valerate products?

The competitive field is fragmented. Generic manufacturers and contract development organizations can compete through ANDA filings, private-label supply, or branded topical platforms. Major commercial competitors include manufacturers of:

• Generic betamethasone valerate cream, ointment, lotion, and foam
• Hydrocortisone and hydrocortisone butyrate
• Triamcinolone acetonide
• Mometasone furoate
• Fluocinolone acetonide
• Desonide
• Clobetasol propionate
• Betamethasone dipropionate

There is no biosimilar challenge pathway because betamethasone valerate is a small-molecule drug. The relevant challenge is generic substitution and vehicle competition.

What patent litigation affects betamethasone valerate?

Betamethasone valerate has no widely recognized current litigation profile comparable with high-revenue small molecules or biologics. The molecule’s age and generic availability reduce the likelihood of high-value composition-of-matter disputes.

Litigation risk can still arise from:

• Alleged infringement of foam or aerosol patents
• Trade dress and product appearance
• Labeling and promotional claims
• Formulation patents
• ANDA Paragraph IV litigation
• Contract manufacturing disputes
• Patent ownership or licensing disputes
• Product liability claims related to corticosteroid overuse

A company developing a new vehicle should conduct a freedom-to-operate review focused on topical delivery patents, aerosol packaging, polymer systems, preservative technologies, and combination products. The relevant claims may not name betamethasone valerate specifically.

What commercial opportunities exist for excipient innovation?

Scalp and hair-bearing skin

A non-greasy foam, lotion, or spray can improve application to the scalp. The product should minimize hair matting, residue, and dripping. A metered spray or foam also creates potential differentiation through controlled dosing.

Sensitive-skin formulations

A fragrance-free, low-irritancy product with reduced glycols and a carefully selected preservative system may compete in dermatology and direct-to-consumer channels. Claims must remain within approved labeling and cannot imply superior safety without supporting evidence.

Barrier-support systems

A betamethasone valerate product could incorporate compatible emollients or barrier-support ingredients such as ceramide systems, glycerin, or selected fatty components. The technical risk is interaction between the corticosteroid, emulsifier system, preservative, and barrier ingredients. A combination product may trigger additional regulatory and patent analysis.

Low-residue body lotion

A quick-drying lotion could target large-area eczema and dermatitis treatment. The development challenge is preventing runoff while maintaining uniform dosing and adequate drug release.

Pediatric-oriented packaging

Child-resistant, dose-controlled, and low-transfer packaging can improve usability. Pediatric positioning requires careful labeling and safety support because topical corticosteroid exposure can be clinically significant in children.

International product adaptation

The same active ingredient may have different potency classifications, reference products, labeling requirements, and excipient restrictions across the United States, European Union, United Kingdom, Canada, and emerging markets. A platform developed for several jurisdictions should avoid excipients that create avoidable regulatory rework.

How does betamethasone valerate compare with competing topical corticosteroids?

Product category	Typical commercial advantage	Main limitation
Betamethasone valerate cream	Established prescribing and generic availability	Limited product-level differentiation
Betamethasone valerate ointment	Occlusion and treatment of dry lesions	Greasy sensory profile
Betamethasone valerate lotion	Large-area and hairy-skin application	Potential runoff and lower residence time
Betamethasone valerate foam	Rapid spreading and scalp usability	Higher manufacturing and packaging complexity
Hydrocortisone products	Lower potency and broad consumer familiarity	May be inadequate for moderate disease
Triamcinolone acetonide	Broad generic availability and multiple vehicles	Strong price competition
Mometasone furoate	Branded and generic vehicle options	Different potency and labeling profile
Clobetasol propionate	High potency for severe localized disease	Greater safety restrictions and narrower use

Betamethasone valerate is most defensible commercially where the product improves usability without materially increasing corticosteroid exposure.

What manufacturing and intellectual-property barriers exist?

Manufacturing barriers are higher for foam, aerosol, and suspension products than for conventional creams. Critical controls include:

• Drug uniformity
• Emulsion droplet size
• Rheology
• Filling accuracy
• Propellant ratio
• Valve and actuator performance
• Microbial limits
• Preservative effectiveness
• Temperature-cycle stability
• Container compatibility
• In vitro release consistency

For semisolid products, scale-up can change viscosity, droplet size, drug crystallization, and release behavior. These changes can affect regulatory comparability even when the qualitative formula remains unchanged.

The strongest IP position is likely to come from a narrowly defined formulation with demonstrated performance advantages. Broad claims covering ordinary cream excipients are vulnerable to prior art and obviousness challenges.

What is the revenue exposure and generic launch risk?

Revenue exposure depends on the product’s dosage form and commercial positioning. A commodity betamethasone valerate cream is highly exposed to price erosion. A differentiated foam, scalp product, or low-residue formulation has greater pricing potential but faces a smaller addressable market and higher development costs.

Product strategy	Price erosion risk	Development complexity	Differentiation potential
Standard cream	High	Low	Low
Standard ointment	High	Low	Low
Lotion	Moderate to high	Moderate	Moderate
Foam	Moderate	High	High
Metered spray	Moderate	High	High
Preservative-conscious cream	Moderate	Moderate	Moderate
Barrier-support combination	Moderate	High	High, with added regulatory risk

Generic launch risk is highest when the proposed product relies on the same reference product, has no enforceable formulation patent, and competes primarily on price. The risk is lower when the product has a differentiated dosage form, reliable supply, strong payer or pharmacy access, and a clear patient-use advantage.

Key Takeaways

1. Betamethasone valerate is a mature generic corticosteroid with little value in active-ingredient exclusivity.
2. Excipients are the main route to commercial differentiation.
3. Foam, scalp lotion, spray, and low-residue body formulations offer the strongest product opportunities.
4. Propylene glycol, ethanol, preservatives, surfactants, and fragrance require careful irritation and tolerability assessment.
5. Conventional cream and ointment products face substantial price competition.
6. New patents are more credible for defined vehicle, packaging, stabilization, or delivery technologies than for routine excipient combinations.
7. The product has no biosimilar risk; competition comes from generic ANDA products and alternative topical corticosteroids.
8. Manufacturing and quality risks increase sharply for foam, aerosol, and suspension systems.
9. Revenue durability depends on formulation differentiation, distribution, and patient adherence rather than molecule exclusivity.
10. A commercial program should prioritize a measurable vehicle advantage supported by comparative release, stability, and usability data.

FAQs

Can betamethasone valerate be formulated without propylene glycol?

Yes. A developer can use alternative solvent, emulsion, suspension, or anhydrous systems. The replacement must maintain drug uniformity, release performance, stability, and skin tolerability.

Is betamethasone valerate foam more commercially attractive than cream?

Often, yes, particularly for scalp and hair-bearing skin. Foam has higher development and packaging costs but can support stronger differentiation and better sensory performance.

Can a ceramide-containing betamethasone valerate product obtain new patent protection?

Potentially, but a patent would require claims that are novel and non-obvious. The strongest case would link the excipient system to a demonstrated technical result, such as improved stability, reduced irritation, or enhanced barrier recovery.

Does a new betamethasone valerate lotion require clinical trials?

Not necessarily. The required evidence depends on the reference product, dosage form, formulation differences, FDA guidance, and the proposed ANDA or NDA strategy. Topical products may require in vitro release, comparative characterization, and additional performance or clinical evidence.

What is the highest-value excipient opportunity for betamethasone valerate?

A low-residue, rapidly spreading scalp or body vehicle is the strongest general opportunity. It addresses adherence and usability while avoiding reliance on expired active-ingredient exclusivity.

References

1. U.S. Food and Drug Administration. (2023a). Betamethasone valerate topical products: Prescribing information and labeling. DailyMed. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (2023b). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2023c). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

4. U.S. Food and Drug Administration. (2022). Product-specific guidance for industry: Betamethasone valerate topical products. https://www.fda.gov/drugs

5. European Medicines Agency. (2023). Guideline on quality and equivalence of topical products. https://www.ema.europa.eu/

6. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.